Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.
Article
PubMed
Google Scholar
Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn P, et al. Clinicopathologic Features of Advanced Squamous NSCLC. J Thorac Oncol. 2016;11(9):1411–22. https://doi.org/10.1016/j.jtho.2016.05.024.
Article
PubMed
Google Scholar
Datta D, Lahiri B. Preoperative Evaluation of Patients Undergoing Lung Resection Surgery. Chest. 2003;123(6):2096–103. https://doi.org/10.1378/chest.123.6.2096.
Article
PubMed
Google Scholar
NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014;383(9928):1561–71. https://doi.org/10.1016/S0140-6736(13)62159-5.
Article
CAS
PubMed Central
Google Scholar
Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, Le Chevalier T, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010;375(9722):1267–77. https://doi.org/10.1016/S0140-6736(10)60059-1.
Article
CAS
PubMed
Google Scholar
Shi Y, Sun Y, Yu J, Ding C, Wang Z, Wang C, et al. China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016 version). Asia Pac J Clin Oncol. 2017;13(1):87–103. https://doi.org/10.1111/ajco.12608.
Article
PubMed
Google Scholar
Sun C, Mezzadra R, Schumacher TN. Regulation and Function of the PD-L1 Checkpoint. Immunity. 2018;48(3):434–52. https://doi.org/10.1016/j.immuni.2018.03.014.
Article
CAS
PubMed
PubMed Central
Google Scholar
He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020;30(8):660–9. https://doi.org/10.1038/s41422-020-0343-4.
Article
PubMed
PubMed Central
Google Scholar
Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–5. https://doi.org/10.1126/science.aar4060.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hoy SM. Sintilimab: First Global Approval. Drugs. 2019;79(3):341–6. https://doi.org/10.1007/s40265-019-1066-z.
Article
CAS
PubMed
Google Scholar
Zhang L, Mai W, Jiang W, Geng Q. Sintilimab: A Promising Anti-Tumor PD-1 Antibody. Front Oncol. 2020;10: 594558. https://doi.org/10.3389/fonc.2020.594558.
Article
PubMed
PubMed Central
Google Scholar
National Medical Products Administration. (2021). Drug Approval Documents Released on June 3, 2021. https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20210603160927171.html [Accessed 22 Feb 2022].
National Medical Products Administration. (2021). Drug Approval Documents Released on June 25, 2021. https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20210625204754172.html [Accessed 22 Feb 2022].
National Medical Products Administration. (2021). Drug Approval Documents Released on February 2, 2021. https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20210202223610138.html [Accessed 22 Feb 2022].
Gao S, Li N, Gao S, Xue Q, Ying J, Wang S, et al. Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. J Thorac Oncol. 2020;15(5):816–26. https://doi.org/10.1016/j.jtho.2020.01.017.
Article
CAS
PubMed
Google Scholar
Gao S, Li N, Gao S, Xue Q, Wang S, Lv F, et al. Two-year follow-up of single PD-1 blockade in neoadjuvant resectable NSCLC. J Clin Oncol. 2021;39(15_suppl):8522. https://doi.org/10.1200/JCO.2021.39.15_suppl.8522.
Article
Google Scholar
Yang Y, Wang Z, Fang J, Yu Q, Han B, Cang S, et al. Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11). J Thorac Oncol. 2020;15(10):1636–46. https://doi.org/10.1016/j.jtho.2020.07.014.
Article
CAS
PubMed
Google Scholar
Zhou C, Wu L, Fan Y, Wang Z, Liu L, Chen G, et al. Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12). J Thorac Oncol. 2021;16(9):1501–11. https://doi.org/10.1016/j.jtho.2021.04.011.
Article
CAS
PubMed
Google Scholar
National Comprehensive Cancer Network. (2021). NCCN Guidelines, Non-Small Cell Lung Cancer. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450 [Accessed 22 Feb 2022].
Gubens MA, Davies M. NCCN Guidelines Updates: New Immunotherapy Strategies for Improving Outcomes in Non-Small Cell Lung Cancer. J Natl Compr Canc Netw. 2019;17(5.5):574–8. https://doi.org/10.6004/jnccn.2019.5005.
Article
PubMed
Google Scholar
Ettinger DS, Wood DE, Aggarwal C, Aisner DL, Akerley W, Bauman JR, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. J Natl Compr Canc Netw. 2019;17(12):1464–72. https://doi.org/10.6004/jnccn.2019.0059.
Article
CAS
PubMed
Google Scholar
Sanaei M, Pourbagheri-Sigaroodi A, Kaveh V, Abolghasemi H, Ghaffari SH, Momeny M, et al. Recent advances in immune checkpoint therapy in non-small cell lung cancer and opportunities for nanoparticle-based therapy. Eur J Pharmacol. 2021;909: 174404. https://doi.org/10.1016/j.ejphar.2021.174404.
Article
CAS
PubMed
Google Scholar
Gan J, Huang Y, Fang W, Zhang L. Research progress in immune checkpoint inhibitors for lung cancer in China. Ther Adv Med Oncol. 2021;13:17588359211029826. https://doi.org/10.1177/17588359211029826.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhang S, Zhang M, Wu W, Yuan Z, Tsun A, Wu M, et al. Preclinical characterization of Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer. Antib Ther. 2018;1(2):65–73. https://doi.org/10.1093/abt/tby005.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ma M, Qi H, Hu C, Xu Z, Wu F, Wang N, et al. The binding epitope of sintilimab on PD-1 revealed by AbMap. Acta Biochim Biophys Sin (Shanghai). 2021;53(5):628–35. https://doi.org/10.1093/abbs/gmab020.
Article
CAS
Google Scholar
Wang J, Fei K, Jing H, Wu Z, Wu W, Zhou S, et al. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. MAbs. 2019;11(8):1443–51. https://doi.org/10.1080/19420862.2019.1654303.
Article
CAS
PubMed
PubMed Central
Google Scholar
Shi Y, Su H, Song Y, Jiang W, Sun X, Qian W, et al. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2019;6(1):e12–9. https://doi.org/10.1016/S2352-3026(18)30192-3.
Article
PubMed
Google Scholar
Xu J, Jia R, Wang Y, Liu R, Zhao C, Zhou H, et al. A first-in-human phase 1a trial of sintilimab (IBI308), a monoclonal antibody targeting programmed death-1 (PD-1), in Chinese patients with advanced solid tumors. J Clin Oncol. 2018;36(15_suppl):e15125. https://doi.org/10.1200/JCO.2018.36.15_suppl.e15125.
Article
Google Scholar
Collins J, Stern EJ. Ground-glass opacity at CT: the ABCs. AJR Am J Roentgenol. 1997;169(2):355–67. https://doi.org/10.2214/ajr.169.2.9242736.
Article
CAS
PubMed
Google Scholar
Chen J, Xie F, Zheng X, Li Y, Liu S, Ma KC, et al. Mobile 3-dimensional (3D) C-arm system-assisted transbronchial biopsy and ablation for ground-glass opacity pulmonary nodules: a case report. Transl Lung Cancer Res. 2021;10(7):3312–9. https://doi.org/10.21037/tlcr-21-561.
Article
PubMed
PubMed Central
Google Scholar
Migliore M, Fornito M, Palazzolo M, Criscione A, Gangemi M, Borrata F, et al. Ground glass opacities management in the lung cancer screening era. Ann Transl Med. 2018;6(5):90. https://doi.org/10.21037/atm.2017.07.28.
Article
PubMed
PubMed Central
Google Scholar
Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e278S-e313S. https://doi.org/10.1378/chest.12-2359.
Article
CAS
PubMed
Google Scholar
Yin R, Xu L, Xia W. 1232P - An exploratory study of a PD-1 inhibitor for high-risk multiple ground-glass nodules (mGGNs) in synchronous stage I non-small cell lung cancer patients. Ann Oncol. 2020;31(suppl_4):S735-43.
Google Scholar
Cheng B, Li C, Zhao Y, He J. The efficacy of PD-1 antibody sintilimab on ground glass opacity lesions in patients with early-stage multiple primary lung cancer (CCTC-1901, NCT04026841). J Clin Oncol. 2021;39(15_suppl):8545. https://doi.org/10.1200/JCO.2021.39.15_suppl.8545.
Article
Google Scholar
Liang H, Liu Z, Cai X, Pan Z, Chen D, Li C, et al. PD‐(L)1 inhibitors vs. chemotherapy vs. their combination in front‐line treatment for NSCLC: An indirect comparison. Int J Cancer. 2019;145(11):3011–21. https://doi.org/10.1002/ijc.32366.
Article
CAS
PubMed
Google Scholar
Jiang H, Zheng Y, Qian J, Mao C, Xu X, Li N, et al. Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study. Cancer Immunol Immunother. 2021;70(3):857–68. https://doi.org/10.1007/s00262-020-02738-x.
Article
CAS
PubMed
Google Scholar
Yang Y, Sun J, Wang Z, Fang J, Yu Q, Han B, et al. Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study. J Thorac Oncol. 2021. https://doi.org/10.1016/j.jtho.2021.07.015.
Article
PubMed
PubMed Central
Google Scholar
Innovent. (2021). The U.S. FDA has accepted the market listing application of sintilimab in combination with pemetrexed and platinum for the treatment of non-squamous non-small cell lung cancer as a first-line therapy. http://cn.innoventbio.com/#/news/259 [Accessed 22 Feb 2022].
Lin X, Deng H, Li S, Xie X, Chen C, Cai L, et al. Sintilimab with chemotherapy as first-line treatment for locally advanced or metastatic squamous non-small-cell lung cancer: a real-world data study. J Cancer Res Clin Oncol. 2022. https://doi.org/10.1007/s00432-021-03903-0.
Article
PubMed
Google Scholar
Zhou C, Gao G, Wu L, Wang Z, Chen G, Huang D, et al. Subgroup analysis of ORIENT-12: Efficacy of sintilimab in combination with gemcitabine and platinum- based chemotherapy in patients with advanced or metastatic squamous non-small cell lung cancer. Ann Oncol. 2021;32(suppl_7):S1428-57. https://doi.org/10.1016/annonc/annonc787.
Article
Google Scholar
Zhang P, Dai J, Sun F, Xia H, He W, Duan L, et al. Neoadjuvant Sintilimab and Chemotherapy for Resectable Stage IIIA Non-small-cell Lung Cancer. Ann Thorac Surg. 2022. https://doi.org/10.1016/j.athoracsur.2022.01.039.
Article
PubMed
Google Scholar
Wang Z, Han X, Guo J, Zhu D, Zhang X, Tang X. 402P - Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC). Ann Oncol. 2020;31(suppl_6):S1386-406. https://doi.org/10.1016/annonc/annonc367.
Article
Google Scholar
Wang Z, Han X, Guo J, Tang X, Zhu C, Zhu H, et al. 14P - Circulating tumor DNA (ctDNA) residual and dynamics of ctDNA clonality indicated therapeutic efficacy of Sintilimab plus Docetaxel in previously treated advanced non-small cell lung cancer. Ann Oncol. 2021;32(suppl_7):S1373-91. https://doi.org/10.1016/annonc/annonc784.
Article
Google Scholar
ClinicalTrials.gov. (2021). Homepage. https://clinicaltrials.gov [Accessed 22 Feb 2022].
Mohsenzadegan M, Peng RW, Roudi R. Dendritic cell/cytokine-induced killer cell-based immunotherapy in lung cancer: What we know and future landscape. J Cell Physiol. 2020;235(1):74–86. https://doi.org/10.1002/jcp.28977.
Article
CAS
PubMed
Google Scholar
Leon E, Ranganathan R, Savoldo B. Adoptive T cell therapy: Boosting the immune system to fight cancer. Semin Immunol. 2020;49: 101437. https://doi.org/10.1016/j.smim.2020.101437.
Article
CAS
PubMed
PubMed Central
Google Scholar
Li R, Wang C, Liu L, Du C, Cao S, Yu J, et al. Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother. 2012;61(11):2125–33. https://doi.org/10.1007/s00262-012-1260-2.
Article
CAS
PubMed
Google Scholar
Ren X, Zhou L. A single-arm phase Ib study of autologous cytokine-induced killer (CIK) cell immunotherapy in combination with sintilimab plus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)-CCICC-002. J Clin Oncol. 2021;15:2531. https://doi.org/10.1016/annonc/annonc367.
Article
Google Scholar
Kordbacheh T, Honeychurch J, Blackhall F, Faivre-Finn C, Illidge T. Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms. Ann Oncol. 2018;29(2):301–10. https://doi.org/10.1093/annonc/mdx790.
Article
CAS
PubMed
Google Scholar
Bernstein MB, Krishnan S, Hodge JW, Chang JY. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol. 2016;13(8):516–24. https://doi.org/10.1038/nrclinonc.2016.30.
Article
CAS
PubMed
PubMed Central
Google Scholar
Andruska N, Stowe HB, Crockett C, Liu W, Palma D, Faivre-Finn C, et al. Stereotactic Radiation for Lung Cancer: A Practical Approach to Challenging Scenarios. J Thorac Oncol. 2021;16(7):1075–85. https://doi.org/10.1016/j.jtho.2021.04.002.
Article
PubMed
Google Scholar
Yin L, Xue J, Li R, Zhou L, Deng L, Chen L, et al. Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2020;108(1):212–24. https://doi.org/10.1016/j.ijrobp.2020.05.002.
Article
PubMed
Google Scholar
Li R, Chen L, Zhang Y, Mei LY, Zhou L, Zhu X, et al. Safety and Tolerability Evaluation of Sintilimab in Combination with Low Dose Radiation and SBRT in Treatment Naive Stage IV PD-L1 Positive NSCLC Patients. Int J Radiat Oncol Biol Phys. 2020;108S(3):S72–3.
Article
Google Scholar
ClinicalTrials.gov. (2021). Search results. https://clinicaltrials.gov/ct2/results?cond=lung+cancer&term=sintilimab+radiotherapy&cntry=&state=&city=&dist= [Accessed 22 Feb 2022].
Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med. 1992;176(6):1693–702. https://doi.org/10.1084/jem.176.6.1693.
Article
CAS
PubMed
Google Scholar
ClinicalTrials.gov. (2021). NCT04106180. https://clinicaltrials.gov/ct2/show/NCT04106180?term=NCT04106180&draw=2&rank=1 [Accessed February 22, 2022].
Ni J, Zhou Y, Wu L, Ai X, Dong X, Chu Q, et al. Sintilimab, stereotactic body radiotherapy and granulocyte–macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial. Radiat Oncol. 2021;16(1):177. https://doi.org/10.1186/s13014-021-01905-3.
Article
CAS
PubMed
PubMed Central
Google Scholar
Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11(1):120. https://doi.org/10.1186/s13045-018-0664-7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Han B, Li K, Zhao Y, Li B, Cheng Y, Zhou J, et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). Br J Cancer. 2018;118(5):654–61. https://doi.org/10.1038/bjc.2017.478.
Article
CAS
PubMed
PubMed Central
Google Scholar
Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, et al. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. Jama Oncol. 2018;4(11):1569–75. https://doi.org/10.1001/jamaoncol.2018.3039.
Article
PubMed
PubMed Central
Google Scholar
Chu T, Zhong R, Zhong H, Zhang B, Zhang W, Shi C, et al. Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC. J Thorac Oncol. 2021;16(4):643–52. https://doi.org/10.1016/j.jtho.2020.11.026.
Article
CAS
PubMed
Google Scholar
Chinese Clinical Trial Registry. (2019). ChiCTR1900025651. https://www.chictr.org.cn/showproj.aspx?proj=40288 [Accessed 22 Feb 2022].
Chinese Clinical Trial Registry. (2019). ChiCTR1900023074. https://www.chictr.org.cn/showproj.aspx?proj=38877 [Accessed 22 Feb 2022].
Chinese Clinical Trial Registry. (2020). ChiCTR2000034888. https://www.chictr.org.cn/showproj.aspx?proj=56928 [Accessed 22 Feb 2022].
Zhang L, Mai W, Hao B, Jiang W, Geng Q. Promising response to a PD-1 inhibitor (sintilimab) in non-small cell lung cancer: A case report. Medicine (Baltimore). 2020;99(21): e19790. https://doi.org/10.1097/MD.0000000000019790.
Article
Google Scholar
Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2020;367:6477. https://doi.org/10.1126/science.aax0182.
Article
CAS
Google Scholar
Ren S, Xu A, Lin Y, Camidge DR, Di Maio M, Califano R, et al. A narrative review of primary research endpoints of neoadjuvant therapy for lung cancer: past, present and future. Transl Lung Cancer Res. 2021;10(7):3264–75. https://doi.org/10.21037/tlcr-21-259.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ulas EB, Dickhoff C, Schneiders FL, Senan S, Bahce I. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review. ESMO Open. 2021;6(5): 100244. https://doi.org/10.1016/j.esmoop.2021.100244.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhao Z, Gao Y, Xue Q, Gao S, He J. Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review. Targ Oncol. 2021;16(4):425–34. https://doi.org/10.1007/s11523-021-00818-1.
Article
Google Scholar
Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med. 2018;378(21):1976–86. https://doi.org/10.1056/NEJMoa1716078.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ling Y, Li N, Li L, Guo C, Wei J, Yuan P, et al. Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes. NPJ Precis Oncol. 2020;4(1):32. https://doi.org/10.1038/s41698-020-00135-2.
Article
CAS
PubMed
PubMed Central
Google Scholar
Proto C, Ferrara R, Signorelli D, Lo Russo G, Galli G, Imbimbo M, et al. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. Cancer Treat Rev. 2019;75:39–51. https://doi.org/10.1016/j.ctrv.2019.03.004.
Article
CAS
PubMed
Google Scholar
Wang S, Yuan P, Mao B, Li N, Ying J, Tao X, et al. Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade. NPJ Precis Oncol. 2022;6(1):2. https://doi.org/10.1038/s41698-021-00244-6.
Article
PubMed
PubMed Central
Google Scholar
Tao X, Li N, Wu N, He J, Ying J, Gao S, et al. The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2020;47(5):1209–19. https://doi.org/10.1007/s00259-020-04711-3.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kerr KM, Tsao MS, Nicholson AG, Yatabe Y, Wistuba II, Hirsch FR. Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art? J Thorac Oncol. 2015;10(7):985–9. https://doi.org/10.1097/JTO.0000000000000526.
Article
CAS
PubMed
Google Scholar
Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol. 2016;27(1):147–53. https://doi.org/10.1093/annonc/mdv489.
Article
CAS
PubMed
Google Scholar
Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, et al. Tracking the Evolution of Non-Small-Cell Lung Cancer. N Engl J Med. 2017;376(22):2109–21. https://doi.org/10.1056/NEJMoa1616288.
Article
CAS
PubMed
Google Scholar
Mansfield AS, Aubry MC, Moser JC, Harrington SM, Dronca RS, Park SS, et al. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann Oncol. 2016;27(10):1953–8. https://doi.org/10.1093/annonc/mdw289.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sheng J, Fang W, Yu J, Chen N, Zhan J, Ma Y, et al. Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer. Sci Rep. 2016;6:20090. https://doi.org/10.1038/srep20090.
Article
CAS
PubMed
PubMed Central
Google Scholar
McNamara MG, Jacobs T, Lamarca A, Hubner RA, Valle JW, Amir E. Impact of high tumor mutational burden in solid tumors and challenges for biomarker application. Cancer Treat Rev. 2020;89: 102084. https://doi.org/10.1016/j.ctrv.2020.102084.
Article
CAS
PubMed
Google Scholar
Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Sci. 2015;348(6230):124–8. https://doi.org/10.1126/science.aaa1348.
Article
CAS
Google Scholar
Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018;24(9):1441–8. https://doi.org/10.1038/s41591-018-0134-3.
Article
CAS
PubMed
Google Scholar
Honrubia-Peris B, Garde-Noguera J, García-Sánchez J, Piera-Molons N, Llombart-Cussac A, Fernández-Murga ML. Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy. Cancers. 2021;13(17):4280. https://doi.org/10.3390/cancers13174280.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nabet BY, Esfahani MS, Moding EJ, Hamilton EG, Chabon JJ, Rizvi H, et al. Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. Cell. 2020;183(2):363–76. https://doi.org/10.1016/j.cell.2020.09.001.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chavez A, Keegan N, Khamashta MA, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):39. https://doi.org/10.1038/s41572-020-0160-6.
Article
Google Scholar
National Institutes of Health. (2019). Common Terminology Criteria for Adverse Events (CTCAE). https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm [Accessed 22 Feb 2022].
Xu C, Chen Y, Du X, Liu J, Huang C, Chen L, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ. 2018;363: k4226. https://doi.org/10.1136/bmj.k4226.
Article
PubMed
PubMed Central
Google Scholar
Wang DY, Salem J, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors. Jama Oncol. 2018;4(12):1721. https://doi.org/10.1001/jamaoncol.2018.3923.
Article
PubMed
PubMed Central
Google Scholar
Zhou X, Yao Z, Bai H, Duan J, Wang Z, Wang X, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncol. 2021;22(9):1265–74. https://doi.org/10.1016/S1470-2045(21)00333-8.
Article
CAS
PubMed
Google Scholar
Wang M, Liang H, Wang W, Zhao S, Cai X, Zhao Y, et al. Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non–small cell lung cancer: A meta-analysis of randomized control trials. Cancer. 2021;127(5):777–86. https://doi.org/10.1002/cncr.33270.
Article
CAS
PubMed
Google Scholar
Rotte A, Jin JY, Lemaire V. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Ann Oncol. 2018;29(1):71–83. https://doi.org/10.1093/annonc/mdx686.
Article
CAS
PubMed
Google Scholar
Lam VK, Forde PM. Another Brick in the Wall: Sintilimab Plus Chemotherapy in Advanced Lung Cancer. J Thorac Oncol. 2020;15(10):1556–8. https://doi.org/10.1016/j.jtho.2020.08.013.
Article
PubMed
Google Scholar